Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579675 | 0.77 | PDE10A (0.58) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL5643188 | 0.77 | PDE10A (0.48) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL294121 | 0.77 | PDE10A (0.58) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL601835 | 0.75 | HTT (0.50) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL799695 | 0.75 | ALDH1A1 (0.51) | KMT2AMEN1PDE10APOLBALDH1A1 | |
| SCHEMBL251801 | 0.75 | MAPT (0.45) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL15681921 | 0.75 | KMT2A (0.43) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL7014776 | 0.75 | KMT2A (0.43) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL5700168 | 0.75 | MEN1 (0.43) | KMT2AMEN1PDE10APOLBNPC1 | |
| SCHEMBL541486 | 0.75 | NPC1 (0.51) | KMT2AMEN1PDE10APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-110914280-A | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triaza derivatives | 阿尤米制药公司 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | KMT2A 43/4885MEN1 2870/4885PDE10A 4770/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | KMT2A 43/4885MEN1 2870/4885PDE10A 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.